ada standards of care 2025 obesity pharmacotherapy glp-1 Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society 2025 ADA Standards of Care:

GLP-1s for Osteoarthritis GLP-1 drugs may slow the progression of osteoarthritis, as research has found that people on the drugs lost more weight and had fewer knee surgeries than people not taking a GLP-1

For diabetes management, indefinite therapy is generally appropriate as long as benefits persist and the medication is tolerated

Its unknown whether the same will be seen in humans, but semaglutide is not recommended for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)

Compounded medication considerations Compounded GLP-1 medications are not FDA-approved products